INTRODUCTION
Combination antiretroviral therapy (cART) signifi cantly reduces mortality in HIV-infected children. One class of antiretroviral drug commonly used in cART are the protease inhibitors (PIs). These drugs are now mostly given with ritonavir, which inhibits their metabolism and boosts PI levels. Recently, our group reported on the long-term safety and effectiveness of mainly unboosted PI-based cART in HIV-1-infected children enrolled in the Swiss Mother and Child HIV Cohort Study (MoCHiV). 1 As boosted PIs have now become the standard of care, we have updated these analyses focusing on children treated with lopinavir boosted with ritonavir (LPV/r).
PATIENTS AND METHODS
HIV-1-infected children living in Switzerland are prospectively followed by MoCHiV 2 according to a common protocol and by use of structured data collection forms. Ethics approval was granted by the cantonal ethical committees of each participating centre and written informed consent of participants' caregivers is obtained before inclusion. As outlined elsewhere, 1 children were seen before starting or changing cART and at weeks 4 and 12, and every 12 weeks thereafter. The dosage of LPV/r was 300 mg/75 mg/m 2 twice daily Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children for all children (adult dose for those ≥13 years of age). Adherence was assessed by self-declaration at each visit (fi ve possible answers for the number of missed doses). Adverse events and abnormal laboratory results (DAIDS grade 3 or 4) 3 during LPV/r treatment were considered as possible side effects, however treatment decisions were left to the treating physician's assessment. Reasons for switching or stopping treatment were verifi ed by chart review.
All children <18 years of age treated with LPV/r between November 2000 (paediatric approval) and October 2008 were included. Children were defi ned as PI-naive if they had not received PI previously, and PI-experienced if they had been given PI as part of previous cART.
Plasma HIV-1 RNA loads were determined in real time using the Amplicor HIV Monitor kit (Roche, Basel, Switzerland) and CD4 cells using fl ow cytometry. HIV-1 replication was considered suppressed if HIV-1 RNA was <50 copies/ml.
Data analysis
We analysed the fi rst LPV/r treatment episode for each child, unless it lasted <30 days and was followed by a subsequent longer episode, which was then examined instead. Baseline was defi ned as the time of initiation of the examined LPV/r episode.
Immunological and virological responses were analysed at 6-monthly (24-week) intervals. Median (interquartile (IQR)) changes from baseline and the percentage of patients with suppressed HIV-1 replication were summarised at each time point. Patients who stopped LPV/r before the examined time point or had insuffi cient follow-up were either excluded from the analysis at that time point or, as a sensitivity analysis, we carried the last available measurement forward and imputed it for all subsequent time points (last observation carry forward).
In patients with detectable viral loads when starting LPV/r, we determined the time to complete virological suppression (defi ned as the fi rst of two consecutive measurements of <50 copies/ ml) or time to stopping LPV/r without viral suppression, whichever came fi rst, using cumulative incidence functions. Viral rebound was defi ned as the fi rst of two consecutive HIV-1 RNA loads of >400 copies/ml or one HIV-1 RNA load of >400 copies/ml plus a subsequent cessation of LPV/r within 91 days.
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Drug therapy
Of 49 children with complete viral suppression (including nine suppressed at baseline), viral rebound occurred in four PI-naive and three PI-experienced children during 124 patient-years of follow-up (5.65 events per 100 patient-years). Median time to viral rebound was 2.18 (range 1.63-3.72 years; 2.59 (2.17-3.72) in PI-naive and 1.85 (1.63-2.75) years in PI-experienced children).
After 48 weeks of LPV/r, median (IQR) increases in CD4 counts and CD4 percentages were 429 (203-593) cells/μl and 10% (3-18%) in PI-naive and 177 (21-331) cells/μl and 6% (2-9%) in PI-experienced patients.
Treatment interruptions and side effects
Forty two children (48%), including seven with viral rebound and 12 with possible toxicity, stopped their LPV/r-based regimen during follow-up. For the remaining 23 children, the reasons for stopping treatment were: withdrawal from the cohort (n=7), patient's or physician's wish or decision (n=6 and n=4, respectively), structured treatment interruption (n=3) and unknown (n=3).
Among the 12 children with suspected toxicity, adverse events were: gastrointestinal in fi ve (including liver and pancreas in one each), and related to fat redistribution, the nervous system, the endocrine system, cardiovascular disease, hypersensitivity, blood count abnormality and unspecifi ed in one each. Grade 3 or 4 laboratory abnormalities 3 were documented in 27 children, but only three children stopped LPV/r (thrombocytopenia (11×10 9 /l without recovery after treatment cessation), a liver enzyme elevation (aspartate aminotransferase 185 IU/l) and an amylase elevation (870 IU/ml without elevation of serum lipase) in one each). Eleven of the 12 children with suspected toxicity restarted a LPV/r-based cART again after a median (IQR) interval of 0.98 (0.52-2.79) years. We observed no deaths on LPV/r.
DISCUSSION
The goal of the present study was to address the long-term safety and effectiveness of LPV/r-based cART in a populationbased cohort of HIV-1-infected children.
Our results show similar proportions of children with undetectable viral loads after 48 weeks as in the initial phase
Statistical methods
The duration of ongoing LPV/r treatment episodes was estimated using the Kaplan-Meier method. All analyses were performed with R 2.8.0 (R Foundation for Statistical Computing, Vienna, Austria) and SAS 9.1 (SAS Institute, Cary, North Carolina, USA).
RESULTS
Our analysis included the fi rst LPV/r treatment episode of 84 children and the second (after a preceding episode of <30 (9-17) days of four children (251 patient-years). Baseline characteristics are summarised in table 1.
Twenty-fi ve children (28%) were PI-naive including 16 (18%) who had never had any antiretroviral therapy. Seven PI-naive children had previously had other ART for a median time of 1.6 (IQR 0.7-3.1) years, (zidovudine alone (n=3) or in combination with lamivudine (n=2), or non-PI based cART (n=2)).
Sixty-three (72%) children were PI-experienced (142 treatment episodes; ritonavir (n=28), nelfi navir (n=17) or both (n=18)). Median time from the fi rst PI-based regimen until treatment with LPV/r was 4.3 (IQR 3.2-6.1) years. Earlier PIs were most frequently combined with lamivudine/zidovudine (42 episodes) or lamivudine/stavudine (22 episodes).
The median duration of a LPV/r treatment episode was estimated at 3.86 (95% CI 2.61 to 5.19) years.
Virological and immunological responses
This analysis was based on 70 (17 PI-naive, 53 PI-experienced) patients for whom baseline and at least one follow-up measurement of HIV-1 RNA and CD4 cells was available (fi gure 1).
Of 61 patients with detectable viral load when starting LPV/r, 40 (66%) achieved complete viral suppression (13/15 (87%) PI-naive and 27/46 (59%) PI-experienced children). Median (IQR) time to full suppression was 180 (153-211) days in PI-naive and 152 (95-242) days in PI-experienced children. Fifteen patients (25%; two PI-naive, 13 PI-experienced) stopped LPV/r before reaching complete viral suppression. After 48 weeks of LPV/r, median (IQR) decreases in viral load were 4.25 (5.45-3.17) in PI-naive and 2.53 (3.68-1.38) in PI-experienced patients. 
Drug therapy
was introduced into clinical use later than these other PIs, direct comparison is not feasible. Of note, median time to achieve viral suppression seems to be much longer in children than in adults. 4 The proportion of children stopping cART (48%) for various reasons was higher than reported elsewhere. 5 However, treatment failure (n=7) and toxicity (n=12) accounted for only 45% of this group. Laboratory abnormalities were associated I/II study of 100 children treated with LPV/r (69% in PI-naive and 54% in PI-experienced children). We also saw similar increases in CD4 cells (404 cells/μl in PI-naive and 284 cells/ μl in PI-experienced children). These virological and immunological effects observed in our cohort were maintained until week 192 in the 25 children who remained on LPV/r. These results with LPV/r compare favourably with fi ndings from our earlier study with ritonavir or nelfi navir. However, as LPV/r with only three children who stopped treatment. Most children with suspected clinical toxicities re-started LPV/r-based regimens. Limitations of our study include the fact that adherence was only assessed by self-declaration and viral resistance and drug levels were not routinely examined.
PI-experienced patients
In conclusion, our data indicate that long-term treatment with LPV/r-based cART is well tolerated, safe and effective in HIV-1-infected children. 
